DS

David Simpson

CEO

Iksuda Therapeutics

Rowlands Gill, England


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Iksuda Therapeutics
Industry
research
Employees
43.0
Seniority
C suite
Annual Revenue
2500000.0
Total Funding
73886299.0
Latest Funding
Other

Technologies

Cloudflare DNS Outlook Microsoft Office 365 CloudFlare Hosting Mobile Friendly Google Tag Manager reCAPTCHA Render AI

Keywords

antibodydrug conjugates permalink conjugation chemistry cancer research adcs drug development therapeutics antibodies toxins cancer treatment adc stability antibody drug conjugate drug discovery biotechnology preclinical bioconjugation organic synthesis clinical cell biology chemistry licencing biotechnology research antibody-drug conjugates adc development tumor-selective activation payload delivery cancer therapy design principles clinical trials targeted therapy oncology innovations differentiated technology pipeline development tumor specificity payload mechanisms novel linkers drug conjugates anti-cancer efficacy patient safety b-cell malignancies her2-targeting gi tumors solid tumors non-hodgkin lymphoma clinical-stage adcs therapeutic index collaborative partnerships drug loading bioengineering tumor-selective payloads research collaborations precision oncology advanced tumor therapy drug resistance solutions high unmet need cancers prodrug mechanisms treatment paradigms biologics manufacturing adc innovation safety profiles advanced linkers novel payloads immunotherapy cancer indications preclinical studies therapeutic options target identification clinical utility multi-platform approach in-house capabilities health care health wellness & fitness hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans